CVRx (CVRX)

• Market cap: $163M
• 1 day: 1.63%
• 5 days: -4.87%
• 1 month: -46.81%
• 3 months: -64.53%
• 6 months: -22.84%
• Year to date: -53.98%
• 1 year: -60.22%
• 5 years: -77.68%
• 10 years: -77.68%
• Sector: Healthcare
• Industry: Medical Devices

About: CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Employees: 206

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

496% more call options, than puts

Call options by funds: $1.03M | Put options by funds: $173K

82% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 11

55% more capital invested

Capital invested by funds: $124M [Q3] → $192M (+$68M) [Q4]

9% more funds holding

Funds holding: 85 [Q3] → 93 (+8) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

2.35% less ownership

Funds ownership: 64.82% [Q3] → 62.47% (-2.35%) [Q4]

10% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 29

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $14 124% upside
• Avg. target: $17.33 177% upside
• High target: $20 220% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Lake Street Frank Takkinen 10% 1-year accuracy 2 / 21 met price target	124% upside $14	Buy Maintained	8 Apr 2025
Canaccord Genuity William Plovanic 37% 1-year accuracy 18 / 49 met price target	188% upside $18	Buy Maintained	8 Apr 2025
Piper Sandler Matt O'Brien 32% 1-year accuracy 16 / 50 met price target	220% upside $20	Overweight Maintained	5 Feb 2025